These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3778112)

  • 1. Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients.
    Zemlan FP; Hirschowitz J; Garver DL
    Arch Gen Psychiatry; 1986 Dec; 43(12):1162-7. PubMed ID: 3778112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
    Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
    Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems.
    Hirschowitz J; Zemlan FP; Hitzemann RJ; Fleischmann RL; Garver DL
    Biol Psychiatry; 1986 May; 21(5-6):445-54. PubMed ID: 3697435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological studies of DSM-III psychotic disorders. I. Platelet measures and apomorphine-induced growth hormone response.
    Meltzer HY; Perline R; Lewine R
    J Nerv Ment Dis; 1982 Dec; 170(12):758-65. PubMed ID: 6754871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noradrenergic and dopaminergic interrelation in schizophrenia.
    Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
    Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates.
    Lieberman JA; Jody D; Alvir JM; Ashtari M; Levy DL; Bogerts B; Degreef G; Mayerhoff DI; Cooper T
    Arch Gen Psychiatry; 1993 May; 50(5):357-68. PubMed ID: 8489325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine.
    Zemlan FP; Hirschowitz J; Sautter F; Garver DL
    Psychiatry Res; 1986 Jul; 18(3):239-55. PubMed ID: 2875478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
    Whalley LJ; Christie JE; Brown S; Arbuthnott GW
    Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone responses to graded doses of apomorphine HCl in schizophrenia.
    Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
    Biol Psychiatry; 1983 Aug; 18(8):875-85. PubMed ID: 6137249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.
    Sharma RP; Javaid JI; Pandey GN; Janicak PG; Davis JM
    Biol Psychiatry; 1991 Sep; 30(5):459-66. PubMed ID: 1657221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multihormonal responses to apomorphine in mental illness.
    Mokrani MC; Duval F; Crocq MA; Bailey PE; Macher JP
    Psychoneuroendocrinology; 1995; 20(4):365-75. PubMed ID: 8532820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach.
    Peralta V; Cuesta MJ
    J Affect Disord; 2008 May; 108(1-2):71-86. PubMed ID: 18029027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone response to apomorphine and family patterns of illness.
    Sautter F; Garver DL; Zemlan FP; Hirschowitz J
    Biol Psychiatry; 1987 Jun; 22(6):717-24. PubMed ID: 3474033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone response to apomorphine.
    Ferrier IN; Johnstone EC; Crow TJ
    Arch Gen Psychiatry; 1987 Jan; 44(1):93-4. PubMed ID: 3800586
    [No Abstract]   [Full Text] [Related]  

  • 15. Longitudinal instability of hormone responses in schizophrenia.
    Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):545-9. PubMed ID: 6686692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thought disorder. A function of schizophrenia, mania, or psychosis?
    Marengo J; Harrow M
    J Nerv Ment Dis; 1985 Jan; 173(1):35-41. PubMed ID: 3965610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mood-incongruent versus mood-congruent psychosis: differential antipsychotic response to lithium therapy.
    Zemlan FP; Hirschowitz J; Garver DL
    Psychiatry Res; 1984 Apr; 11(4):317-28. PubMed ID: 6588396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients.
    Müller-Spahn F; Modell S; Ackenheil M; Brachner A; Kurtz G
    J Psychiatr Res; 1998; 32(5):265-71. PubMed ID: 9789204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced growth hormone response to apomorphine in schizophrenic patients with poor premorbid social functioning.
    Malas KL; van Kammen DP; de Fraites EA; Brown GM; Gold PW
    J Neural Transm; 1987; 69(3-4):319-24. PubMed ID: 3625198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.